# Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.

> **NCT00742495** · PHASE1,PHASE2 · TERMINATED · sponsor: **Mundipharma Research Limited** · enrollment: 2 (actual)

## Conditions studied

- Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia
- B-cell Precursor Acute Lymphoblastic Leukaemia
- T-cell Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Forodesine

## Key facts

- **NCT ID:** NCT00742495
- **Lead sponsor:** Mundipharma Research Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-03
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Slow Recruitment
- **Last updated:** 2012-10-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00742495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00742495, "Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00742495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*